Histone deacetylase (HDAC) inhibitors represent a promising new therapy against malignant glioma. When used in conjunction with oncolytic viral vectors, these compounds have been shown to augment virotherapy. In the current study, we examined the antitumor effect of combining the lytic animal virus equine herpesvirus type 1 (EHV-1) with the HDAC inhibitor valproic acid (VPA). Pretreatment of two human glioblastoma cell lines (U251 and SNB19) with VPA resulted in a significant increase in virus entry, replication, cell to cell spread and cell lysis. Overall, these data indicate that VPA significantly improves EHV-1-mediated oncolysis of human glioma cells that are only moderately killed by EHV-1 alone.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor in humans. 1 These aggressive tumors are highly resistant to standard modes of treatment including surgical resection, radiotherapy and chemotherapy. The median survival rate of GBM patients is 12-18 months with aggressive therapy, [2] [3] [4] and o5% of patients survive out to 5 years. 5, 6 Therefore, new treatment options are desperately needed for GBM patients.
One novel treatment option that has become increasingly popular is the use of viruses for oncolytic therapy. Many viruses have been evaluated for their oncolytic potential against human gliomas, including human herpes simplex virus type 1 (HSV-1), 7 adenovirus, 8 vesicular stomatitis virus, 9 Newcastle disease virus, 10 myxoma virus 11 and vaccinia virus. 12 We recently showed that the animal virus equine herpesvirus type 1 (EHV-1) can effectively enter and kill human glioma cells. 13 EHV-1 is a member of the alphaherpesvirus family, which includes the human herpes simplex viruses HSV-1 and HSV-2.
14 EHV-1 has many attributes that make it an attractive candidate for oncolytic virotherapy against GBM. Some of these favorable properties include: (1) the virus is well characterized and the genome has been sequenced, thus allowing for the rational design of various recombinant viruses; 15 (2) EHV-1 has a short replication cycle and infection results in the lysis of cells; 16 and (3) humans have no preexisting antibodies to the virus. 17 In an effort to enhance the oncolytic ability of viral vectors, researchers have examined the effect of delivering chemical adjuvants in combination with these viruses on glioma cells. One group of compounds that has been shown to significantly enhance virotherapy is histone deacetylase (HDAC) inhibitors. HDACs are responsible for the deacetylation of histone proteins on chromosomes, which leads to a selective increase in gene expression. 18 The HDAC inhibitors valproic acid (VPA), trichostatin A and FR901228 have all been shown to enhance oncolysis mediated by various viral vectors including adenovirus, 8 adenoassociated virus, 19 vaccinia virus 20 and HSV-1. 21 These HDAC inhibitors augment virotherapy in a variety of ways, including upregulating virus entry receptors, [22] [23] [24] increasing viral replication 8, 25 and inhibiting interferons. 26, 27 Collectively, data obtained from these studies show that HDAC inhibitors alter the microenvironment of the tumor in ways that allow for better virus infection and lysis of cancer cells.
We previously reported that certain human glioma cell lines are more susceptible to EHV-1 than others. 13 As an ongoing challenge to viral oncolytic therapy is the ability of the virus to kill a large number of the existing tumor cells, the current study evaluated the ability of VPA to enhance the EHV-1-mediated oncolysis of U251 and SNB19 glioma cells, which are two GBM cell lines that are moderately susceptible to EHV-1 infection. 13 Data collected in this study show that treatment of U251 and SNB19 cells with VPA before EHV-1 infection results in a significant increase in EHV-1 entry, replication, cell to cell spread (CTCS) and cell lysis compared with viral infection alone.
MATERIALS AND METHODS

Cell lines, reagents and virus
Human glioblastoma lines (U251 and SNB19) were purchased from ATCC (Manassas, VA, USA). Rabbit kidney (RK13) cells were kindly provided by Dennis O'Callaghan (Louisiana State University Health Sciences Center, Shreveport, LA, USA). All cell lines were maintained at 37 1C and 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U ml À 1 penicillin and 100 mg ml À 1 streptomycin. The HDAC inhibitor VPA was purchased from EMD Chemicals (San Diego, CA, USA). The recombinant EHV-1 LacZ reporter virus, L11DgIDgE, was described previously. 28 L11DgIDgE was derived from the pathogenic RacL11 strain and is deleted for glycoproteins I (gI) and E (gE). In place of these glycoproteins, a LacZ reporter cassette has been inserted. This allows for production of b-galactosidase (b-gal) in infected cells, which can be measured quantitatively with ONPG (ortho-nitrophenyl-b-D-galactoside) and qualitatively with X-gal (5-bromo-4-chloro-3-indolyl-b-Dgalactopyranoside).
Cytotoxicity assays
The extent of glioma cell death mediated by EHV-1 alone or in conjunction with VPA was measured using an MTS assay. This assay assesses the metabolic activity of cells by measuring the reduction of the tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] to formazan. The MTS assay was performed using the Promega CellTiter 96 AQ ueous One Solution Cell Proliferation Assay kit (Madison, WI, USA). Cells were seeded in a 96-well plate at a cell density of 1 Â 10 4 cells per well in triplicate. For the pretreatment assay, the cells were untreated or treated with 30 mM VPA in 30 ml of DMEM for 2.5 h. After this time, 70 ml of maintenance DMEM was added to all wells. At 24 h after addition of inhibitor, the VPA and media were removed from the wells and cells were washed with 100 ml of DMEM. Cells were then mock-infected or infected with L11DgIDgE at multiplicities of infection (MOIs) of 1, 3 and 10. An additional column of cells served as a total cell death control and did not receive any virus. For the co-treatment assay, 30 mM VPA was added at the same time as the virus. Virus was incubated on the cells for 2 h in 30 ml of DMEM. For the pretreatment assay, the virus and media mixture were then removed and 100 ml of DMEM was added to each well. For the co-treatment assay, the virus was removed, replaced with VPA media for 22 h and then replaced with DMEM for the remaining 24 h. At 48 h post infection (p.i.), the cells in the total cell death control wells were lysed with 10 ml lysis buffer (10% Triton X-100) for 5 min. Media was removed from all wells and each well was washed with 100 ml serum-and phenol red-free DMEM (Lonza, Walkersville, MD, USA). Assay mixture (100 ml) consisting of five parts phenol red-free DMEM to one part MTS solution from the Promega kit was then added to each well. The plate was incubated for 60 min at 37 1C and 5% CO 2 and then read on a plate reader (Multiskan Ascent photometric plate reader, Thermo Electron Corporation, Vantaa, Finland) at 492 nm. For each well, percent cell survival was calculated by determining the average absorbances of that run's mock-infected wells and total cell death wells and the following formula was applied:
abs ðwellÞ À abs ðtotal deathÞ abs ðmockÞ À abs ðtotal deathÞ Á 100. Three trials per cell line were performed and the overall average for each cell line was calculated and graphed.
Infectivity assays
Glioma cells were seeded in a 96-well plate at a cell density of 3 Â 10 4 cells per well in triplicate. For the pretreatment assay, the cells were treated with or without VPA as described above. Cells were then mock-infected or infected with L11DgIDgE at MOIs of 1, 3 and 10. For the co-treatment assay, VPA was added simultaneously with the virus. At 2 h p.i., 70 ml of DMEM was added to each well and the cells were incubated for an additional 4 h. The virus and media mixture were then removed and the cells were washed with 150 ml of phosphate-buffered saline (PBS). ONPG solution (PBS, ONPG, Triton X-100, BME/MgCl 2 ) was added to each well and the plate was incubated for 30 min. The plate was then read at 405 nm on a plate reader to determine the amount of b-gal produced. Each of these triplicated assays was run three times and the average of the absorbances across all data sets was calculated and graphed.
Viral replication assays
Glioma cells were seeded in a 24-well plate at a cell density of 2 Â 10 5 cells per well, with three replicates of ± VPA for each of two time points. Cells were treated with or without VPA for 24 h and then infected with L11DgIDgE at an MOI of 3. At 2 h p.i., cells were washed three times with media and then 500 ml of DMEM was added to each well. The three replicates (cells and media) for each time point were harvested 24 and 48 h p.i. The harvested cells and media were centrifuged at 14 000 r.p.m. for 5 min in a Spectrafuge 16M microcentrifuge (Labnet International, Edison, NJ, USA). The supernatants were transferred to new microcentrifuge tubes and the cell pellets were resuspended in 50 ml of their supernatant. Cell pellets were disrupted to release intracellular virus by three freeze-thaw ( À 80 to 37 1C) cycles. The disrupted cell pellets were then added back to their supernatants and a 10-fold dilution series was generated. The amount of infectious EHV-1 at each time point was quantified using a standard plaque assay on RK13 cells. A total of 100 ml of each dilution from each time point was added to monolayers of RK13 cells and incubated for 1.5 h. Following incubation, 1 ml of 1% methylcellulose in DMEM containing 10% fetal bovine serum was added to each well. Cells and virus were then incubated at 37 1C for 3 days. Cells were fixed, stained with crystal violet and plaques counted to determine the plaque-forming units per ml (PFU per ml) at each time point.
Viral entry kinetics
Glioma cells were seeded in a 96-well plate at a cell density of 3 Â 10 4 cells per well in triplicate. For the pretreatment assay, the cells were untreated or treated with VPA as described in the cytotoxicity assay methods. For the co-treatment assay, VPA was added at the same time as the virus and was kept on the cells for the duration of the assay. After 24 h, the media was removed from the plates and the cells were washed with 100 ml of cold DMEM. Cold DMEM was again added to the wells and the plates were placed on ice for 5 min. After this time, cells were mock-infected or infected on ice with L11DgIDgE at MOIs of 1, 3 or 10 for 2 h. After 2 h, the cells were washed twice with cold DMEM and 100 ml of warm DMEM (37 1C) was added to the wells, allowing for virus entry. At 5, 15, 30 and 60 min after virus entry, the media was removed from the wells and 30 ml of a warm low pH glycine buffer was added for 30 s. Glycine buffer was removed and the cells were washed three times with warm DMEM. Next, 100 ml of warm DMEM was added to the wells and the plate was incubated. At 6 h after virus entry, an ONPG assay was performed as described above. The average of the absorbance values at each of the four time points across all data was calculated and graphed, comparing the untreated cells with the cells treated with VPA.
Cell to cell spread Cells were seeded in a 12-well plate at a cell density of 3 Â 10 5 cells per well. Cells were treated with or without VPA for 24 h, and then infected with B300 PFU of L11DgIDgE and incubated for 2 h. Following incubation, 1 ml of 1% methylcellulose in DMEM containing 10% fetal bovine serum was added to each well. Cells and virus were incubated at 37 1C for 4 days, after which the plate was stained with X-gal as follows. Cells were rinsed with PBS and fixed with a 0.5% glutaraldehyde solution for 10 min. Cells were again rinsed with PBS and X-gal stain was added to each well and incubated at 37 1C for 2 h. X-gal stain was then removed, 1 ml of PBS was added to each well and plaque formation was visualized with an inverted Motic AE21 microscope (British Columbia, Canada). Images were captured using a Moticam 2.0 camera (Motic) at Â 100 magnification.
RESULTS
VPA enhances EHV-1-mediated oncolysis of human glioma cells
In order to determine if VPA could synergize with EHV-1 and enhance viral-mediated oncolysis, an MTS cell viability assay was performed as described in the Materials and Methods. Glioma cells were untreated or treated with VPA for 24 h, mock-infected or infected with the EHV-1 LacZ reporter virus L11DgIDgE 28 at various MOIs, and then cell viability was assessed at 48 h p.i. (Figure 1a) . A significant increase in cell death was observed in the U251 and SNB19 cell lines that were treated with VPA compared with the untreated cells. At each MOI, cell death was significantly increased by VPA pretreatment. At the highest MOI of 10, VPA pretreatment resulted in 70% cell death in both cell lines versus only 10-30% cell death in the untreated cells that were infected with EHV-1. These results show that VPA pretreatment acts synergistically with EHV-1 to kill GBM cells that are only moderately killed by EHV-1 infection alone. Interestingly, cell killing was enhanced by VPA only when the cells were treated for 24 h before infection. No difference in cell viability was observed when VPA and EHV-1 were added to cells at the same time (Figure 1b) . The ability of VPA to enhance cell lysis only when added before EHV-1 infection suggests that treatment of U251 and SNB19 cells with this HDAC inhibitor sensitizes the cells to EHV-1 infection.
VPA enhances EHV-1 infection of human glioma cells In order to assess whether VPA pretreatment increased EHV-1 infection, U251 and SNB19 cells were untreated or treated with VPA for 24 h and then mock-infected or infected with L11DgIDgE
Enhancement of equine herpesvirus 1 virotherapy MC White and AR Frampton at MOIs of 1, 3 and 10 for 6 h. The extent of infection was measured by examining b-gal expression using an ONPG assay as described in the Materials and Methods. As shown in Figure 2a , pretreatment with VPA resulted in a significant increase in infection on the U251 and SNB19 cell lines, most evident at the lower MOIs. However, co-administration of VPA and L11DgIDgE on these cells did not result in enhanced infection (Figure 2b ). This increase in infection with VPA preincubation correlates well with the increase in cell death observed in the cytotoxicity assays with VPA pretreatment.
VPA increases EHV-1 yield in human glioma cells To evaluate if VPA pretreatment enhanced EHV-1 yield in the U251 and SNB19 cell lines, cells were pretreated with or without VPA for 24 h and then infected with L11DgIDgE at an MOI of 3. Cells were harvested 24 and 48 h p.i. and total virus collected at each time point was titered using a standard plaque assay on RK13 cells to determine the number of infectious virus particles or PFU per ml ( Figure 3 ). As shown in Figure 3 , EHV-1 yield in both the U251 and SNB19 cells was increased significantly in the presence of VPA at 24 and 48 h p.i. The VPA-treated U251 cells showed a 0.7 log increase in viral yield at 24 h p.i. and a full log increase at 48 h p.i. compared with the untreated cells. The SNB19 cells exhibited a stronger enhancement of viral replication with VPA pretreatment, with over a full log increase in EHV-1 yield at both time points.
EHV-1 entry is increased with VPA pretreatment The ability of VPA pretreatment to increase infection and cell killing of U251 and SNB19 cells led us to investigate potential mechanisms by which VPA sensitizes cells to EHV-1-mediated lysis. One hypothesis is that VPA pretreatment influences an early stage of EHV-1 infection and results in an increased rate of entry of virus particles into GBM cells. In order to assess whether VPA increased virus entry, cells were pretreated with or without VPA for 24 h and then infected with L11DgIDgE at various MOIs at 4 1C for 2 h. After this attachment period, the temperature was raised to 37 1C to allow for synchronized virus entry. Extracellular virus was neutralized with a low pH glycine buffer at 5, 15, 30 and 60 min after temperature shift. At 6 h after virus entry, the amount of virus that was able to enter cells within the allotted 5, 15, 30 or 60 min was measured by examining b-gal expression using an ONPG assay as described in the Materials and Methods. Figures 4a and b demonstrate that the rate of EHV-1 entry was increased in cells that were treated with VPA 24 h before infection. At an MOI of 10, the absorbance values for the U251 cells pretreated with VPA are roughly twice those of the untreated cells at the same MOI across all time points. The SNB19 cells that had been pretreated with VPA demonstrate a marked increase in absorbance values at all MOIs compared with the untreated cells at all time points. However, co-administration of VPA and L11DgIDgE on both of these cell lines did not result in increased virus entry at any time point (Figures 4a and b) .
Pretreatment with VPA enhances the ability of EHV-1 to spread laterally from cell to cell To assess whether VPA pretreatment enhanced the ability of EHV-1 to spread from cell to cell, glioma cells were treated with or without VPA for 24 h and then infected with B300 PFU of L11DgIDgE for 2 h and then overlaid with 1% DMEM methylcellulose to allow for plaque development. As shown in Figure 5 , pretreatment with VPA resulted in enhanced viral spread in both glioma lines. The number of plaques observed in the U251 cell line increased from 7 to 30 and the number of plaques observed in the SNB19 cell line increased from 2 to 107 with VPA pretreatment (Table 1) . Plaques were defined as four or more adjacent infected cells. The number and size of plaques were both increased after VPA treatment, suggesting that the HDAC inhibitor is enabling the virus to spread more easily to neighboring cells.
DISCUSSION
Because of the refractory nature of GBM to standard cancer therapies, 29 oncolytic virotherapy has become an attractive therapeutic option against these aggressive tumors. An effective, clinical-grade oncolytic virus should first be safe and cause little to no adverse side effects. In addition to safety, the vector should be able to readily infect, replicate in, and ultimately lyse GBM tumor cells. Although many oncolytic viruses display some of these One promising class of compounds that has been shown to synergize with oncolytic virotherapy is the HDAC inhibitors. 31, 32 These HDAC inhibitors have been shown to enhance oncolytic vectors in a variety of ways, including increasing the expression of virus attachment/ entry receptors, 22 enhancing viral replication 8 and interfering with host innate immunity. 26 We previously reported that infection of human glioma cells with the animal virus EHV-1 is highly variable. 13 The glioma cell lines A-172 and LN-18 are highly susceptible to EHV-1 infection, whereas U251 and SNB19 cells are only moderately infected. 13 In an effort to enhance the ability of the virus to kill the moderately infected cell lines (U251 and SNB19), we investigated whether combining the HDAC inhibitor VPA with EHV-1 could augment the antitumor effects of the virus. Not only did we observe a robust increase in viral-mediated cell killing after treatment with VPA, but we also noted a distinct enhancement of the rate of virus entry. These entry data clearly showed that incubation of U251 and SNB19 cells with VPA for 24 h resulted in faster virus entry compared with untreated cells. The enhanced rate of entry was not due to increased attachment of virus to cells, as EHV-1 bound equally well to both cell lines regardless of VPA treatment (data not shown). In addition, the entry kinetics assay revealed that virus entry on both glioma lines occurred very rapidly after the temperature was shifted to 37 1C, as the absorbance values at 5 min were similar to the values recorded at 60 min.
Otsuki et al. 25 demonstrated that pretreatment, but not co-treatment, with VPA enhanced the propagation of an oncolytic HSV-1 vector. The results that we obtained in this study indicate that EHV-1 infection of GBM cells is also only enhanced in cells that were pretreated with VPA. This suggests that for both alphaherpesviruses the HDAC inhibitor is sensitizing the cells to infection. In the case of EHV-1, VPA pretreatment results in a more rapid rate of virus entry into VPA-treated cells. Although a robust increase in infection and cell death was noted after VPA pretreatment, co-treatment with VPA had no effect on EHV-1 infection or viral-mediated oncolysis. These data suggest that the cellular changes induced by VPA that lead to glioma cell sensitization to infection take time to develop, and this is why no difference in infection or cytotoxicity is observed when VPA is added to cells simultaneously with EHV-1.
Interestingly, VPA has been shown to enhance major histocompatibility complex class I (MHC-I) expression in a melanoma cell line. 23, 33 The kinetics data sets obtained in this study suggest that the increased rate of virus entry observed after VPA pretreatment could be due in part to an increase in the number of MHC-I entry receptors that are available for binding by the EHV-1 glycoprotein D. Future studies will be performed to investigate this possible connection between VPA treatment and enhanced EHV-1 entry. In addition to investigating whether VPA increases the expression of EHV-1 entry receptors, we will also examine other possible cellular modifications mediated by VPA that may lead to enhanced EHV-1 infection and lysis of GBM cells. It is known that HDAC activity is required for the successful establishment of an antiviral state in cells and that treatment with HDAC inhibitors prevents transcription of interferonstimulated genes (ISG). 34, 35 As demonstrated with HSV, inhibition of the immune response shortly after infection leads to increased viral propagation in tumor cells. 36 VPA in particular has been shown to counter the innate glioma immune response against oncolytic HSV by inhibiting the induction of ISG 25 as well as by suppressing the recruitment of immune cells to the tumor site in vivo. 26 VPA has also been shown to exhibit antiangiogenic effects in GBM models. 37 Taken together, the accumulated data suggest that the ability of VPA and other HDAC inhibitors to augment virotherapy is multifactorial. The ability of VPA to downregulate the innate immune response of infected cells is of particular interest, as EHV-1 induces a robust secretion of interferon-a upon infection of equine cells. 38 In addition to increasing the ability of EHV-1 to enter cells, VPA treatment also enhances EHV-1 CTCS. The ability of VPA to drastically improve the lateral CTCS of EHV-1 is noteworthy and warrants further investigation. We recently showed that MHC-I expression is critically important for EHV-1 CTCS (unpublished results, AR Frampton), and thus the possible upregulation of MHC-I in GBM cells treated with VPA could contribute to both increased entry and CTCS of the virus. Similarly, the HSV-1 receptor nectin-1 has been shown to play an important role in not only HSV-1 entry but also viral CTCS. 39, 40 A common issue with current oncolytic vectors is their inability to spread fully within the tumor. 41, 42 The HDAC inhibitors VPA and trichostatin A have both been shown to enhance the spread of oncolytic viruses in cancer cells. 20, 25 Administering VPA before EHV-1 infection clearly enables the virus to spread more easily to adjacent glioma cells, an essential property for an effective oncolytic vector.
Our results clearly demonstrate that the timing of VPA administration is crucial in order to obtain a synergistic effect with the virus. This suggests an altering of the cellular environment over time in favor of the virus, and it will be necessary in future studies to further explore how the cells are modified by VPA to allow for increased viral infection, replication, CTCS and tumor cell lysis. Overall, the data presented here show that VPA pretreatment strongly augments EHV-1-mediated oncolysis in U251 and SNB19 glioma cells.
